Showing 531-540 of 1378 results for "".
- New Image-Guided Dermatology Therapy System Receives CE Mark in Europehttps://practicaldermatology.com/news/new-oncology-and-dermatology-device-approved-europe/2463232/Ultrasound tech manufacturer TOOsonix A/S announced that it has received EU Medical Device Regulation (MDR) CE certification for its image-guided dermatologic therapy system, System ONE-M™, according to a news release from the company. The device facilitates the treatment of common skin c
- Impact of Alopecia Areata on Pediatric Patients and Their Families: Insights from a Single-Center Study in Turkeyhttps://practicaldermatology.com/news/impact-alopecia-areata-pediatric-patients-and-their-families-insights-single-center-study-turkey/2462829/Alopecia areata (AA) is known to impact the health-related quality of life (HRQoL) of affected individuals, yet there is a paucity of research focusing on its effects specifically in pediatric patients and their families. To address this gap, researchers recently conducted a single-center cross-s
- Micro-Coring Could Offer Nonsurgical Option for Moderate to Severe Rhytidshttps://practicaldermatology.com/news/micro-coring-offers-nonsurgical-option-moderate-severe-rhytids/2462726/A dermal micro-coring device improved the appearance of moderate-to-severe rhytids on the cheek and lower face after two treatments, according to data from a new study presented at the American Society for Laser Medicine and Surgery 43rd Annual Conference on Energy-based Medicine and S
- Galderma to Showcase Latest Updates From Its Dermatology Portfolio at the 2024 AAD Annual Meetinghttps://practicaldermatology.com/news/galderma-to-showcase-latest-updates-from-its-dermatology-portfolio-at-the-2024-american-academy-of-dermatology-annual-meeting-1/2462259/Galderma will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) annual meeting from March 8-12, 2024, highlighting its dermatology portfolio. Galderma’s presence includes two late-breaking presentations on its first-in-class, investi
- Bimekizumab Shown Safe at 3 Years for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/bimekizumab-shown-safe-at-3-years-for-moderate-to-severe-plaque-psoriasis/2462216/In a poster presented at Maui Derm, 2024, results from a long-term pooled analysis from five phase-3/3b trials indicate that bimekizumab (BKZ) is safe and well-tolerated at the 3-year mark in patients with moderate-to-s
- NPs and PAs Value Prognostic Information From DecisionDx-Melanomahttps://practicaldermatology.com/news/nps-and-pas-value-prognostic-information-from-decisiondx-melanoma/2462163/More than 90% of nurse practitioners and physician assistants(NPs/PAs), agree that prognostic information about a patient’s melanoma is valuable and improves patient care, , according to new study looking at use of DecisionDx-Melanoma in the Jo
- Derm-Biome Pharmaceuticals, Massachusetts General Hospital Partner for Skin Cancer Study of New Topical Rxhttps://practicaldermatology.com/news/derm-biome-pharmaceuticals-massachusetts-general-hospital-partner-for-skin-cancer-study-of-new-topical-rx/2462157/Derm-Biome Pharmaceuticals Inc. is collaborating with Massachusetts General Hospital for a study looking at Derm-Biome’s second-generation topical treatment for precancerous skin conditions and non-melanoma skin cancers. The topical is highly sel
- FDA Grants Priority Review for Abeona's Pz-cel BLAhttps://practicaldermatology.com/news/fda-grants-priority-review-for-abeonas-pz-cel-bla/2462154/The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Biologics License Application (BLA) of Abeona Therapeutics Inc.’s pz-cel (prademagene zamikeracel), an investigational autologous, COL7A1 gene-corrected epidermal sheets for the treatment of patient
- Take That, Melanoma! ATM Kinase Inhibitors May Stop Metastasishttps://practicaldermatology.com/news/take-that-melanona-atm-kinase-inhibitors-may-stop-metastasis/2462146/Ataxia telangiectasia mutated (ATM) kinase inhibition may target the metastatic capacity of melanoma cells, according to a research team led by Wolfgang Weninger and Shweta Tikoo from MedUni Vienna's Department of Dermatology. The results of the study, which appe
- AD Pipeline Watch: Rademikibart Maintains Efficacy Out to Week 52https://practicaldermatology.com/news/ad-pipeline-watch-rademikibart-maintains-efficacy-out-to-week-52/2462145/Connect Biopharma’s rademikibart continues to wow in patients with moderate-to-severe atopic dermatitis, according to topline results from the Stage 2 (maintenance period) of its China pivotal trial. Rademikibart is an inhibitory human monoclonal antibody against the IL-4Rα